Journal of Viral Hepatitis

Papers
(The TQCC of Journal of Viral Hepatitis is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Issue Information43
Issue Information37
International disease burden of acute viral hepatitis among adolescents and young adults: An observational study30
29
Persistence of immunity against hepatitis A in Brazilian children vaccinated with a single dose of inactivated virus vaccine24
Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England23
Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents22
Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease22
Cost‐effectiveness analysis of an active search to retrieve HCV patients lost to follow‐up (RELINK‐C strategy) and the impact of COVID‐1922
Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B21
240‐week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C21
The role of serum sphingolipids as potential biomarkers of non‐response to direct acting antiviral therapy in chronic hepatitis C virus infection21
Baseline Alpha‐Fetoprotein Elevation and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B: A Multicentre Cohort Study20
Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues20
Issue Information19
Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab19
Hepatitis A occurrence and outbreaks in Europe over the past two decades: A systematic review18
A cross‐sectional study of hepatitis C prevalence and correlates among persons who inject drugs in rural and non‐rural communities18
Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination18
Issue Information17
16
Issue Information15
Contribution of alcohol use in HIV/hepatitis C virus co‐infection to all‐cause and cause‐specific mortality: A collaboration of cohort studies15
Sex‐related difference analyses of efficacy and safety in clinical trials of direct‐acting antivirals to treat chronic HCV genotype 1 and 3 infections15
Elevation of S2‐bound α1‐acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma15
Direct‐acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment15
Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000‐Korean outcome study15
Improvement of chronic HCV infection‐related depression, anxiety, and neurocognitive performance in persons achieving SVR‐12: A real‐world cohort study15
Infectivity of Hepatitis B Virus Surface Antigen‐Positive Plasma With Undetectable HBV‐DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?14
Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment14
Trends and Socio‐Demographic Patterns of Hepatitis B Virus Hospitalisations in Poland: A 12‐Year Nationwide Analysis14
Long‐Term Follow‐Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon‐Free and Interferon‐Based Hepatitis C Virus Treatment14
TRPM2 regulates autophagy to participate in hepatitis B virus replication14
A Network Map of Intracellular Alpha‐Fetoprotein Signalling in Hepatocellular Carcinoma14
Adenovirus vector encoding TPPII ignites HBV‐specific CTL response by activating autophagy in CD8+ T cell14
Integration and the risk of liver cancer—Is there a real risk?14
Reversibility of acute‐on‐chronic liver failure syndrome in hepatitis B virus‐infected patients with and without prior decompensation14
Issue Information14
A declaration from people living with hepatitis B: A call for a whole person approach13
Safe co‐administration of direct‐acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study13
Issue Information13
An updated assessment of hepatitis delta prevalence among adults in Canada: A meta‐analysis13
The role of treatment of hepatitis C with direct‐acting antiviral agents on glycaemic control in diabetic patients: An updated systematic review and meta‐analysis13
Effect of liver steatosis on liver stiffness measurement in chronic hepatitis B patients with normal serum alanine aminotransferase levels: A multicentre cohort study12
Challenges of hepatitis B treatment in rural Sub‐Saharan Africa: Treatment initiation and outcomes from a public hospital‐based clinic in Kono, Sierra Leone11
Measuring stigma associated with hepatitis B virus infection in Sierra Leone: Validation of an abridged Berger HIV stigma scale11
HCV hotline facilitates Hepatitis C elimination during the COVID‐19 pandemic11
Viral hepatitis in pregnancy11
Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver‐related complications in patients with chronic hepatitis C receiving direct‐acting antiviral agents11
Electronic nose versus quadrupole mass spectrometry for identifying viral hepatitis C patients10
Sustainable and equivalent improvements in symptoms and functional well‐being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: 10
Strategies to increase primary care provider capacity for hepatitis C care: The California ECHO‐PLUS study10
Prevalence of hepatitis C in sexual assault survivors presenting to a SANE clinic: A descriptive analysis10
10
Epidemiology and Outcomes of Hepatitis E Virus‐Associated Hospitalisations in the United States With a Focus on Pregnancy: A Nationwide Population Study, 1998–202010
10
Serum HBV RNA is associated with liver fibrosis regression in HBeAg‐positive chronic hepatitis B patients treated with nucleos(t)ide analogues10
Risk of drug‐induced liver injury in chronic hepatitis B and tuberculosis co‐infection: A systematic review and meta‐analysis9
Baseline and on‐treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals9
Hepatitis E prevalence and infection in solid‐organ transplant recipients in the United States9
Epidemiological Burden of Hepatitis Delta Virus in the United States9
Efficacy of an eConsult service to cure hepatitis C in primary care9
Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO Study9
The changing epidemiology of delta hepatitis in Türkiye over three decades: A systematic review9
Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta‐analysis9
Systematic Screening for Hepatitis B, C, and HIV and Linkage to Care in Patients With Mental Health Disorders Admitted to the Emergency Department9
Issue Information9
9
Network‐basedstrategies to combatHCV: Examining social and spatial drivers of transmission amongPWIDin New Delhi9
Clinical and histological features of patients with chronic hepatitis B virus infection in the grey zone9
Cover image9
Does hepatitis delta virus have a preference for hepatitis B virus genotype? A systematic review of the literature9
Mixed‐Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis9
VirA+EmiC project: Evaluating real‐world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department8
The immune landscape in hepatitis delta virus infection—Still an open field8
The altered HLA‐DQ expression in peripheral blood T cells of chronic hepatitis B patients characterizes the function of T cells8
Prognostic value of genotyping in hepatocellular carcinoma: A systematic review8
Dynamic personalized prediction of the individual liver‐related risk after sustained viral response in HCV patients8
Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States8
Hepatitis D virus infection: Progress on the path toward disease control and cure8
Hepatitis B e antigen and e antibody in a multi‐ethnic cohort of adult chronic hepatitis B virus patients followed at a single liver unit for a period of 20 years8
Clinical and patient‐reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™8
Factors affecting long‐term changes of liver stiffness in direct‐acting anti‐hepatitis C virus therapy: A multicentre prospective study8
Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi‐ethnic population: Universal screening is more comprehensive8
A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP‐HEPC t7
Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection7
7
7
The Efficacy and Sustainability of an Implementation Intervention (FOCUS Program) on Linkage to Hepatitis C Care Time at a Community Health Center in the Deep South: A Longitudinal Study Ba7
CHB patients with rtA181T‐mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes7
Serum α‐fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct‐acting antiviral treatme7
A novel test and treat program for hepatitis C virus infection utilizing HCV core antigen testing, among police and general population, Islamabad, Pakistan, 20227
Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon‐based therapy7
Socioeconomic Deprivation Weighs Heavily on Liver Fibrosis and Mortality After Hepatitis C Cure (ANRS CO22 Hepather)7
Long‐term benefits of interferon‐α therapy in children with HBeAg‐positive immune‐active chronic hepatitis B7
Performance of HCV core antigen and PCR testing in a predominantly genotype 3 population7
Risk factors for hepatitis C virus infection at a large urban emergency department7
Duration of Nucleos(t)ide Analogue Treatments in Patients With Chronic Hepatitis B Virus Infection in the United States7
Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure6
Issue Information6
Reply to ‘Assessing the hepatitis C epidemiology in Switzerland: It’s not that trivial’6
Mortality and morbidity related to hepatitis C virus infection in hospitalized adults—A propensity score matched analysis6
Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon‐alfa6
Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis6
Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct‐acting antivirals6
6
MELD score < 18 rule out 28‐day ACLF development among inpatients with hepatitis B‐related previous compensated liver disease6
Substance use and CD4/CD8 ratio in HIV/HCV co‐infected people receiving direct‐acting antiviral treatment (ANRS CO13 HEPAVIH)6
CORRIGENDUM6
Phase 1 study of safety and tolerability of an oral contraceptive containing low‐dose ethinyl oestradiol combined with glecaprevir/pibrentasvir treatment in healthy premenopausal women6
Persistent chronic immune activation in HIV/HBV‐coinfected patients after antiretroviral therapy6
Screening rates for hepatitis B and C among low‐income US veterans: Data from the National Veteran Homeless and Other Poverty Experiences Study6
Impact of COVID‐19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs6
Balancing Efficiency and Accuracy in Hepatitis C Rapid Antibody Testing: Insights From a Cluster Randomised Crossover Trial6
Severe acute hepatitis of unknown origin in children: Is it still a mystery? What role does adenovirus play?6
Cigarette Smoking Is Associated With Lower Chance of Hepatitis B Surface Antigen Seroclearance and Altered Host Immunity6
6
Hepatitis B screening practices and viral control among persons living with HIV in urban Senegal6
Preferences and feasibility of long‐acting technologies for treatment of hepatitis C virus in low‐ and middle‐income countries: A survey of providers and policymakers6
A Qualitative Systematic Review of Barriers and Facilitators to Hepatitis B and C Programmes in Prisons6
Barriers and enablers to people‐centred viral hepatitis care in Vietnam and the Philippines: Results of a patient journey mapping study6
Hepatitis Delta Coinfection Rates and All‐Cause Mortality Among Hepatitis B‐Infected Veterans in the USA6
Post‐vaccination serologic testing of infants born to hepatitis B surface antigen‐positive mothers is more cost‐effective in Zhejiang Province, China: A Markov chain analysis6
Persistence of antibodies 5 years after hepatitis B vaccination in preterm birth children: A retrospective cohort study using real‐world data5
Chronic viral hepatitis C micro‐elimination program using telemedicine in Guigang city5
A Programme of Hepatitis C Surveillance With Active Linkage to Care (HEAL) for Inpatients in Two Tertiary Hospitals in Jiangsu, China5
Screening, Prevalence and Management of Chronic Viral Hepatitis C in Mental Health Setting: Towards the Eradication of A Forgotten Reservoir5
Outcomes of a 1‐Year Pilot Study Implementing Universal Hepatitis Delta Virus Testing Among Veterans With Chronic Hepatitis B5
Depletion of circ_0088046 suppressed cell growth and motility of hepatocellular carcinoma via circ_0088046‐miR‐1299‐RTKN2 ceRNA pathway5
5
Recognisable Alcohol Use Significantly Increases the Risk of Adverse Outcomes in Patients With Hepatitis B Virus‐Related Cirrhosis5
Maternal chronic hepatitis B virus infection and the risk of preterm birth: A retrospective cohort analysis in Chinese women5
A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype5
Prevalence of hepatitis B virus (HBV) and latent tuberculosis co‐infection and risk of drug‐induced liver injury across two large HBV cohorts in the United 5
HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre‐ and posttreatment: a multicentre observational cohort study5
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection With Interferon or Direct Antiviral Therapy5
Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy5
Genetic substructure and host‐specific natural selection trend across vaccine‐candidate ORF‐2 capsid protein of hepatitis‐E virus5
Closing the hepatitis C treatment gap: United States strategies to improve retention in care5
Cover Image5
Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real‐world analysis5
Outcomes of Assisted Reproductive Technology in Women With Hepatitis B Infection5
Sequence characterization of extracellular HBV RNA in patient plasma5
The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection5
Prevalence of hepatitis C among pregnant women in an Appalachian population5
5
5
Hepatitis C prevalence and elimination planning in Pakistan, a bottom‐up approach accounting for provincial variation5
Long‐term persistence of anti‐HAV antibody conferred by a single dose of live‐attenuated hepatitis A vaccine: Results from 17‐year follow‐up5
5
Hepatocytes and Hepatic Stellate Cells Carry Different Levels of DNA Damage due to Their Sensitivity to Oxidative Stress in Chronic Hepatitis B5
MiRNome Profiling of Circulating Extracellular Vesicles in Patients With Chronic Hepatitis D Undergoing Pegylated Interferon Alpha Treatment5
Issue Information5
0.15243601799011